Key facts
- It has raised $2.0M; the latest was Seed Round ($2.0M) in Oct 2025.
- Notable investors include US National Science Foundation, Endless Frontier Labs, DCVC, Matter (Consulting Services (B2B)), NYU Summer Launchpad — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for OraLiva
- ·The full record, as it builds
Funding rounds
No funding rounds for OraLiva are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OraLiva
Developer of an AI-powered cytology diagnostic platform designed to help early cancer detection and precision oncology care at the point-of-care. The company's platform offers scalable, non-invasive diagnostic tests using advanced AI algorithms, enabling healthcare providers to make faster, more accurate diagnostic decisions, improving patient outcomes, and facilitating early disease intervention.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 3
- Website
- oraliva.com/
- Ownership
- Privately Held (backing)
OraLiva doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OraLiva shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OraLiva in its N-PORT filings yet. We sweep new filings monthly.